| Print
Evolus (EOLS)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Address
520 Newport Center Drive
Suite 1200
Newport Beach
CA
USA
92660
Telephone
+1 949 284-4555
Forecast key dates
Name | Key Date |
---|---|
Evolus Inc First Quarter Earnings Conference Call for 2025 | 2025-05-07T16:30:00 |
Evolus Inc First Quarter Earnings Results for 2025 | 2025-05-07T00:00:00 |
Evolus Inc Fourth Quarter Earnings Conference Call for 2024 | 2025-03-07T16:30:00 |
Evolus Inc Fourth Quarter Earnings Results for 2024 | 2025-03-07T00:00:00 |
Evolus Inc Annual Report for 2024 | 2025-03-07T00:00:00 |
Evolus Inc Third Quarter Earnings Conference Call for 2024 | 2024-11-07T16:30:00 |
Evolus Inc Third Quarter Earnings Results for 2024 | 2024-11-07T00:00:00 |
Evolus Inc Second Quarter Earnings Conference Call for 2024 | 2024-08-02T16:30:00 |
Evolus Inc Second Quarter Earnings Results for 2024 | 2024-08-02T00:00:00 |
Evolus Inc Annual General Meeting for 2024 | 2024-06-07T08:00:00 |
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit | 2024-05-15T00:00:00 |
Evolus Inc First Quarter Earnings Conference Call for 2024 | 2024-05-07T16:30:00 |
Evolus Inc First Quarter Earnings Result for 2024 | 2024-05-07T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.